SYK and systemic lupus erythematosus: Dapirolizumab pegol (DZP) is a polyethylene glycol-conjugated antigen-binding fragment, targeting CD40L which, after its proved efficacy in active SLE,85 showed decreased expression of type I IFN signature in patients with high baseline type I IFN expression.86 Finally, GSK2646264, a spleen tyrosine kinase (SYK) inhibitor with topical application, showed a modest incline of several interferon-related genes, in patients with cutaneous lupus erythematosus (NCT02927457).87